# Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

> **NCT01542684** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 8 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Azacytidine
- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT01542684
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2014-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01542684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01542684, "Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01542684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*